FLGT  valuation analysis

Basics
Name: Fulgent Genetics, Inc
Description: Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. (more)
Industry: Diagnostics & Research
Last 10Q10Qs are quarterly reports which contain a company's financial figures. We use these to calculate the FFER.: May 06, 2021
Market cap: $2.22B (1020th)
Sales(TTM): $773.39M (1081st)
Earnings(TTM): $416.96M (439th)

Value
FFER: 0.92*
Actual price: $76.63
* Earnings were reported Aug 02, 2021 but we do not have the financials for this quarter. This is likely because the company has not yet released them. However, it might also be a problem with data quality. Regardless, you should take the FFER above with a grain of salt until we get updated financials.

Prices as of EOD 2021-07-15
Price & Estimates
Sales & Earnings history (TTM)
Notable
  • Fulgent Genetics, Inc's earnings increased from -$459,000 to $416.96M in the last year.
  • Fulgent Genetics, Inc's sales grew by 2115.3% ($34.91M to $773.39M) over one year against a market average growth of 20.1%.
  • Fulgent Genetics, Inc's operating income increased from -$519,000 to $558.99M in the last year.
Earnings / MarketCap
Fulgent Genetics, Inc
"Diagnostics & Research" industry
Sales / MarketCap
Fulgent Genetics, Inc
"Diagnostics & Research" industry
Book / MarketCap
Fulgent Genetics, Inc
"Diagnostics & Research" industry
Equity / Assets
Fulgent Genetics, Inc
"Diagnostics & Research" industry